Robinson KA, Maimone S, Gococo-Benore DA, et al. - While the incidence of COVID-19 vaccine-induced adenopathy in the research seemed to be low at 3% compared with 16% of self-reported axillary swelling in previous COVID-19 vaccine trials, this incidence is still higher than axillary adenopathy in otherwise normal mammography, which was recorded as 0.02% to 0.04%. As a result, frequent inquiries about the most recent history of COVID-19 vaccination are necessary.

• On mammography, 23 (3%) of 750 women developed axillary adenopathy, but only 2 were symptomatic.

• The median period after vaccination in patients with adenopathy was significantly shorter at 10 days vs 18 days in patients without adenopathy (median [range] 10 [1-28] vs 18 [1-85] days).

• Adenopathy rates dropped as the number of days from vaccination increased, with 15 of 283 (5.3%) for 1 to 14 days, 8 of 272 (2.9%) for 15 to 28 days, and 0 of 195 (0%) for more than 28 days.

• The incidence of adenopathy reduced over time, with no adenopathy detected in patients who had the vaccine more than 28 days prior, supporting the Society of Breast Imaging's guidelines.

• Furthermore, patients who exhibit symptoms of adenopathy are more likely to have adenopathy.

• However, the current study has drawbacks, most notably its small sample size and single-center design.

• As the COVID-19 vaccine becomes more widely available around the world, this study presents timing considerations and potential findings for breast imaging after vaccination.